依达拉奉注射液用于急性脑梗死的疗效观察
|
摘要
目的:探讨依达拉奉注射液用于急性脑梗死的疗效。方法:选取2017年6月至2018年7月江西省新干县人民医院收治的急性脑梗死患者66例,以随机数字表法分为观察组和对照组,每组33例。对照组患者给予常规治疗,观察组患者在对照组的基础上加用依达拉奉注射液。比较两组患者的临床疗效、白细胞介素6(IL-6)、白细胞介素13(IL-13)、内皮素1(ET-1)、丙二醛(MDA)及超氧化物歧化酶(SOD)水平的差异。结果:观察组患者的总有效率为87.88%(29/33),明显高于对照组的63.64%(21/33),差异有统计学意义(P<0.05);治疗后,观察组患者IL-6、IL-13、ET-1、MDA及SOD水平明显优于对照组,差异均有统计学意义(P<0.05)。结论:依达拉奉注射液治疗急性脑梗死的疗效显著。
OBJECTIVE:To probe into the efficacy of edaravone injection in treatment of acute cerebral infarction(ACI). METHODS:66 patients with ACI admitted into Jiangxi Xin'gan County People's Hospital from Jun. 2017 to Jul. 2018 were selected and divided into observation group and control group via random number table, with 33 cases in each. The control group was given conventional therapy, while the observation group was given edaravone injection based on the control group. Differences in clinical efficacy, interleukin-6(IL-6), interleukin-13(IL-13), endothelin-1(ET-1), malondialdehyde(MDA)and superoxide dismutase(SOD) levels between two groups were compared. RESULTS:The total effective rate of observation group was 87.88%(29/33), which was significantly higher than that of the control group(63.64%, 21/33), with statistically significant difference(P<0.05); after treatment, the IL-6, IL-13, ET-1, MDA and SOD levels of observation group were significantly better than those of control group, with statistically significant differences(P<0.05). CONCLUSIONS:The efficacy of edaravone injection in treatment of ACI is remarkable.
OBJECTIVE:To probe into the efficacy of edaravone injection in treatment of acute cerebral infarction(ACI). METHODS:66 patients with ACI admitted into Jiangxi Xin'gan County People's Hospital from Jun. 2017 to Jul. 2018 were selected and divided into observation group and control group via random number table, with 33 cases in each. The control group was given conventional therapy, while the observation group was given edaravone injection based on the control group. Differences in clinical efficacy, interleukin-6(IL-6), interleukin-13(IL-13), endothelin-1(ET-1), malondialdehyde(MDA)and superoxide dismutase(SOD) levels between two groups were compared. RESULTS:The total effective rate of observation group was 87.88%(29/33), which was significantly higher than that of the control group(63.64%, 21/33), with statistically significant difference(P<0.05); after treatment, the IL-6, IL-13, ET-1, MDA and SOD levels of observation group were significantly better than those of control group, with statistically significant differences(P<0.05). CONCLUSIONS:The efficacy of edaravone injection in treatment of ACI is remarkable.
引文
[1] 韦廷求.依达拉奉对急性脑出血患者再灌注损伤的临床疗效观察[J].药物评价研究,2012,35(2):124-125.
[2] 包丽娟,刘宁,胡小娟,等.依达拉奉治疗急性期脑出血Meta分析[J].中国实用神经疾病杂志,2012,15(23):22-24.
[3] 李向彧.依达拉奉联合银杏达莫辅助治疗急性脑梗死患者疗效观察[J].山西医药杂志,2018,47(3):309-311.
[4] 杨宁.疏血通联合依达拉奉治疗急性脑梗死临床观察[J].中国实用神经疾病杂志,2016,19(6):103-104.
[5] 李晓红,郑玉敏,万里姝.依达拉奉治疗急性脑梗死的临床研究[J].现代药物与临床,2014,29(6):639-643.
[6] 孙艳梅,杨学传.依达拉奉治疗35例急性脑出血的临床疗效分析[J].现代预防医学,2012,39(1):252-253.
[7] 卢涛.丁苯酞注射液联合依达拉奉治疗急性脑梗死疗效及安全性观察[J].医学理论与实践,2017,30(18):2696-2698.
[8] 徐程.丁苯酞注射液联合依达拉奉治疗急性脑梗死的疗效观察[J].中国现代药物应用,2018,12(6):99-101
[9] 王明朋,罗文成,杨金球.依达拉奉联合丹参川芎嗪治疗急性脑梗死疗效观察[J].现代中西医结合杂志,2015,24(14):1533-1535.
[10] 曲东显.依达拉奉治疗急性脑梗死的疗效观察[J].中国实用神经疾病杂志,2014,17(19):66,83.
[11] 邱崇帅.血塞通注射液治疗急性脑梗死患者的临床观察[J].中华医药指南,2012,10(27):277-278.
[12] 刘梅.依达拉奉单用、联用丹参川芎嗪治疗急性脑梗死疗效及安全性评估[J].现代中西医结合杂志,2014,23(19):2105-2107.
[13] 赵国庆,李岩松,姜晨辉,等.银杏二萜内酯葡胺注射液联合依达拉奉注射液治疗急性脑梗死的临床疗效观察[J].中医中药,2017,15(30):210-211.
[14] 卫保林,曾引翠,闫晋康.早期应用阿司匹林治疗进展型脑梗死30例疗效观察[J].中西医结合心脑血管病杂志,2012,10(8):945-946.
[15] 肖桂荣,王赵伟,朱仁洋,等.丁苯酞注射液联合依达拉奉治疗急性脑梗死的疗效观察[J].中国神经免疫学和神经病学杂志,2016,23(1):51-54.
[2] 包丽娟,刘宁,胡小娟,等.依达拉奉治疗急性期脑出血Meta分析[J].中国实用神经疾病杂志,2012,15(23):22-24.
[3] 李向彧.依达拉奉联合银杏达莫辅助治疗急性脑梗死患者疗效观察[J].山西医药杂志,2018,47(3):309-311.
[4] 杨宁.疏血通联合依达拉奉治疗急性脑梗死临床观察[J].中国实用神经疾病杂志,2016,19(6):103-104.
[5] 李晓红,郑玉敏,万里姝.依达拉奉治疗急性脑梗死的临床研究[J].现代药物与临床,2014,29(6):639-643.
[6] 孙艳梅,杨学传.依达拉奉治疗35例急性脑出血的临床疗效分析[J].现代预防医学,2012,39(1):252-253.
[7] 卢涛.丁苯酞注射液联合依达拉奉治疗急性脑梗死疗效及安全性观察[J].医学理论与实践,2017,30(18):2696-2698.
[8] 徐程.丁苯酞注射液联合依达拉奉治疗急性脑梗死的疗效观察[J].中国现代药物应用,2018,12(6):99-101
[9] 王明朋,罗文成,杨金球.依达拉奉联合丹参川芎嗪治疗急性脑梗死疗效观察[J].现代中西医结合杂志,2015,24(14):1533-1535.
[10] 曲东显.依达拉奉治疗急性脑梗死的疗效观察[J].中国实用神经疾病杂志,2014,17(19):66,83.
[11] 邱崇帅.血塞通注射液治疗急性脑梗死患者的临床观察[J].中华医药指南,2012,10(27):277-278.
[12] 刘梅.依达拉奉单用、联用丹参川芎嗪治疗急性脑梗死疗效及安全性评估[J].现代中西医结合杂志,2014,23(19):2105-2107.
[13] 赵国庆,李岩松,姜晨辉,等.银杏二萜内酯葡胺注射液联合依达拉奉注射液治疗急性脑梗死的临床疗效观察[J].中医中药,2017,15(30):210-211.
[14] 卫保林,曾引翠,闫晋康.早期应用阿司匹林治疗进展型脑梗死30例疗效观察[J].中西医结合心脑血管病杂志,2012,10(8):945-946.
[15] 肖桂荣,王赵伟,朱仁洋,等.丁苯酞注射液联合依达拉奉治疗急性脑梗死的疗效观察[J].中国神经免疫学和神经病学杂志,2016,23(1):51-54.